N Lakshmi|A G Kumar - JoVE Visualize

Showing results (41-50 of 45) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 45 results.

BMC Pharmacology & Toxicology|May 23, 2013

Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF ratsNagesh Gowda, Anilkumar Dandu, Jaideep Singh, et al.

Cardiovascular Diabetology|January 28, 2014

CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice modelsTharappel M Anil, Chandrashekaran Harish, Mudigere N Lakshmi, et al.

BMC Pharmacology & Toxicology|August 8, 2014

A novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefitsTharappel M Anil, Anilkumar Dandu, KrishnaReddy Harsha, et al.

Circulation|February 4, 1997

Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardiumA G Kumar, C M Ballantyne, L H Michael, et al.

Diabetology & Metabolic Syndrome|August 22, 2014

CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal modelsManoj Kumar Sadasivuni, Bobbili Madhusudhan Reddy, Jaideep Singh, et al.

Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 45 results.

BMC Pharmacology & Toxicology|May 23, 2013

Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF ratsNagesh Gowda, Anilkumar Dandu, Jaideep Singh, et al.

Cardiovascular Diabetology|January 28, 2014

CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice modelsTharappel M Anil, Chandrashekaran Harish, Mudigere N Lakshmi, et al.

BMC Pharmacology & Toxicology|August 8, 2014

A novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefitsTharappel M Anil, Anilkumar Dandu, KrishnaReddy Harsha, et al.

Circulation|February 4, 1997

Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardiumA G Kumar, C M Ballantyne, L H Michael, et al.

Diabetology & Metabolic Syndrome|August 22, 2014

CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal modelsManoj Kumar Sadasivuni, Bobbili Madhusudhan Reddy, Jaideep Singh, et al.

Pageof 5